Archive · 23 Jul 2025
Cancer Progress: Steady Advances, Increased Survival and Prevention
Over the past few decades, we've gotten much better at fighting cancer.
Death rates are down, and more people are surviving.
This is due to better treatments like immunotherapy and vaccines that prevent cancer.
For example, the HPV vaccine has significantly reduced cervical cancer in some countries.
However, not everyone benefits equally.
People in poorer areas and some minority groups still face worse outcomes because they have less access to treatment.
While we haven't found a single cure, these improvements make cancer less deadly, which is a big win.
Cancer death rates have declined in the US and over 140 countries since the 1990s.
Survival rates have increased, with over 85% five-year relative survival for common cancers in high-income countries.
Advances in immunotherapy, such as pembrolizumab and CAR-T cell therapies, have improved treatment outcomes.
Preventive measures, like antismoking campaigns and the HPV vaccine, have reduced cancer incidence.
Progress is uneven, with disparities in access to diagnostics, vaccines, and therapies, particularly in low- and middle-income countries.
- Who
- Cancer patients worldwide.
- What
- Advances in cancer treatment and prevention leading to increased survival rates and decreased death rates.
- When
- Death rates have fallen since the early 1990s.
- Where
- United States and over 140 countries.
- Why
- Due to advancements in earlier detection, improved treatments, and preventive measures.
Areas of Disparity
Progress Made
Access to Resources
Areas of Disparity
People in rural areas or low-income communities often face poorer outcomes despite medical advances.
Progress Made
High-income countries have better access to diagnostic tools, vaccines, and standard therapies.
- US Death Rate Decline
- Roughly a third since the early 1990s
- Estimated Fewer Deaths
- 3 to 4 million in the US
- 5-Year Survival Rate (High-Income)
- Exceeds 85% for many common cancers
- HPV Vaccine Impact
- Reduced cervical cancer incidence by up to 90% in high vaccination rate countries
- Key Treatments
- Immunotherapy (pembrolizumab, dostarlimab, CAR-T)